Analytical Data
-
基因名
DMBT1
- Application
-
别名
GP340; SAG; Muclin; Glycoprotein 340; Hensin; Salivary agglutinin; Surfactant pulmonary-associated D-binding protein
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UGM3
-
表达区间
Thr20~Ser220
-
分子量
33kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DMBT1 (Deleted in Malignant Brain Tumors 1) is a large, glycoprotein involved in various biological processes, including cell adhesion, tumor suppression, and immune response. Initially identified in studies of malignant brain tumors, DMBT1 has garnered attention for its potential role in cancer biology and as a biomarker for certain malignancies. Research indicates that DMBT1 expression is altered in various tumors, suggesting a correlation between its levels and cancer progression. Furthermore, due to its involvement in mucosal immunity and tissue repair, DMBT1 has implications in developmental biology and inflammatory diseases. Studies have focused on the characterization of DMBT1 as a recombinant protein, enabling analysis of its structural properties and functional assays. Recombination techniques facilitate the production of DMBT1 in controlled environments, allowing researchers to explore its interactions with other cellular components and its potential therapeutic applications. Understanding DMBT1’s biochemical pathways could illuminate new avenues for targeted therapies in oncology and regenerative medicine, making it a significant focus of ongoing research in both fundamental and applied biomedical sciences.
